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The vesicular neurotransmitter transporters (VNTs) are small proteins responsible for
packing synaptic vesicles with neurotransmitters thereby determining the amount of
neurotransmitter released per vesicle through fusion in both neurons and glial cells.
Each transporter subtype was classically seen as a specific neuronal marker of the
respective nerve cells containing that particular neurotransmitter or structurally related
neurotransmitters. More recently, however, it has become apparent that common
neurotransmitters can also act as co-transmitters, adding complexity to neurotransmitter
release and suggesting intriguing roles for VNTs therein. We will first describe the current
knowledge on vesicular glutamate transporters (VGLUT1/2/3), the vesicular excitatory
amino acid transporter (VEAT), the vesicular nucleotide transporter (VNUT), vesicular
monoamine transporters (VMAT1/2), the vesicular acetylcholine transporter (VAChT) and
the vesicular γ-aminobutyric acid (GABA) transporter (VGAT) in the brain. We will focus
on evidence regarding transgenic mice with disruptions in VNTs in different models of
seizures and epilepsy. We will also describe the known alterations and reorganizations in
the expression levels of these VNTs in rodent models for temporal lobe epilepsy (TLE)
and in human tissue resected for epilepsy surgery. Finally, we will discuss perspectives
on opportunities and challenges for VNTs as targets for possible future epilepsy therapies.
Keywords: vesicular neurotransmitter transporters, temporal lobe epilepsy, epileptogenesis, antiepileptic drugs,
SLC17 , SLC18, SLC32
INTRODUCTION
Epilepsy is one of the most common acquired chronic neurologic
disorders, affecting approximately 1% of the human population
and displaying an annual incidence of 50,000–100,000 persons
(Pitkänen and Sutula, 2002; Pitkänen and Lukasiuk, 2009; Fridley
et al., 2012). The disorder has disastrous implications for the
quality of life of the patients, concerning independent living,
education and employment, mobility and personal relationships.
In Europe alone, health costs increased considerably, reaching
more than C15.5 billion (Baulac and Pitkanen, 2008). Despite
the availability of a large number of antiepileptic drugs (AEDs),
clinically proven to suppress or prevent seizures, in 30–40% of
patients symptoms cannot be controlled (Baulac and Pitkanen,
2008; Abou-Khalil and Schmidt, 2012).
Epilepsy is characterized by spontaneous, recurrent seizures
(SRS), caused by abnormal synchronized, high frequency neu-
ronal discharges (Pitkänen and Sutula, 2002; Baulac and
Pitkanen, 2008; O’dell et al., 2012). Especially in patients with
temporal lobe epilepsy (TLE), marked by partial complex seizures
of temporal-lobe origin, a progressive development of the disor-
der is observed (Pitkänen and Sutula, 2002; Baulac and Pitkanen,
2008). Generally, TLE is initiated by an initial precipitating injury,
such as status epilepticus (SE), head trauma, brain infection,
stroke, or febrile seizures. This insult triggers a cascade of dev-
astating neurobiological events and histological and biochemical
changes during a latency period of 5–10 years. In this time
range the patient remains free from symptoms or complications,
though an epileptic state is being established in the brain, called
epileptogenesis, leading to the occurrence of SRS and the diag-
nosis of epilepsy (Pitkänen and Sutula, 2002; Sharma et al., 2007;
Pitkänen and Lukasiuk, 2009; O’dell et al., 2012).
The main mechanisms of action of currently available AEDs
can be classified into four broad categories: (1) modulation of
voltage-dependent sodium, calcium (Ca2+) or potassium (K+)
channels, (2) alterations in γ-aminobutyric acid (GABA)ergic
inhibition via actions on GABAA receptors or on GABA synthe-
sis, reuptake or degradation, (3) decreased synaptic excitation
via actions on ionotropic glutamate receptors and (4) modu-
lation of neurotransmitter release via presynaptic mechanisms,
with most relevant action on glutamate release (Porter et al.,
2012) (Figure 1). Despite the fact that some AEDs have proven
neuroprotective properties and act by multiple mechanisms of
action, they are often only transiently effective and anticonvul-
sant. Consequently, treatment might be successful at the onset
of SRS (silent period), however, as the disease progresses, many
patients develop tolerance and become pharmacoresistant (Abou-
Khalil and Schmidt, 2012; Kobow et al., 2012; O’dell et al.,
2012). Alternative therapies are limited and invasive, including
seizure foci resection, vagus nerve stimulation and brain stimu-
lation (Fridley et al., 2012). Obviously, there is an urgent need
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FIGURE 1 | Proposed mechanisms of action of currently available
antiepileptic drugs (AEDs) at excitatory and inhibitory synapses. (A)
Currently available AEDs are thought to target several molecules at the
excitatory synapse. These include voltage-gated Na+ channels, synaptic
vesicle glycoprotein 2A (SV2A), the α2δ subunit of the voltage-gated Ca2+
channel, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)
receptors, and NMDA (N-methyl-d-aspartate) receptors. Many of the AEDs
can modulate voltage-gated Na+ channels. This would be expected to
decrease depolarization-induced Ca2+ influx and vesicular release of
neurotransmitters. Levetiracetam is the only available drug that binds to
SV2A, which might have a role in neurotransmitter release. Gabapentin and
pregabalin bind to the α2δ subunit of voltage-gated Ca2+ channels, which
is thought to be associated with a decrease in neurotransmitter release.
Excitatory neurotransmission at the postsynaptic membrane can be limited
by topiramate (acting on AMPA and kainate receptors) and felbamate
(acting on NMDA receptors). (B) AED targets at inhibitory synapses have
also been proposed. These include the γ-aminobutyric acid (GABA)
transporter GAT1 (also known as SLC6A1), which is inhibited by tiagabine,
leading to a decrease in GABA uptake into presynaptic terminals and
surrounding glia, and GABA transaminase (GABA-T), which is irreversibly
inhibited by vigabatrin. This decreases the metabolism of GABA in
presynaptic terminals and glial cells. The benzodiazepines, barbiturates,
topiramate, and felbamate have been found to enhance inhibitory
neurotransmission by allosterically modulating GABAA receptor-mediated
Cl− currents. However, the action of each of these drugs is different and is
dependent on the subunit conformation of the GABAA receptor complex.
GAD, glutamic acid decarboxylase. Figure is modified, with permission,
from Bialer and White (2010).
of non-invasive treatments that prevent or modify the develop-
ment of epilepsy, in other words, antiepileptogenic or disease-
modifying drugs, respectively (Baulac and Pitkanen, 2008). In
future validation, new targets should be able to achieve at least
one of these two aims (Kobow et al., 2012).
In order to identify new targets, the molecular and cellular
mechanisms behind the genesis of epilepsy need to be unveiled.
Although countless studies have tried to understand the patho-
genesis and progression of TLE, the order of deleterious events
during epileptogenesis still remains unknown (O’dell et al., 2012).
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Moreover, the outcome after the initial insult is considerably vari-
able and at present there are no reliable biomarkers or surrogate
disease markers available (Kobow et al., 2012). Current innova-
tive strategies for future AED targets include ion channels and
other potential molecular targets (see Meldrum and Rogawski,
2007 and Bialer and White, 2010 for recent reviews) such as
neuronal gap junctions (Belousov, 2012; Belousov and Fontes,
2013), neuropeptides (Casillas-Espinosa et al., 2012; Portelli et al.,
2012a,b), astrocytic gap junctions and Kir channels (Kovacs et al.,
2012; Steinhauser et al., 2012), the cystine/glutamate antiporter
or system xc− (De Bundel et al., 2011; Lewerenz et al., 2013),
mTOR (McDaniel and Wong, 2011), distinct inflammatory path-
ways (Vezzani et al., 2013), adenosine kinase (Boison, 2010,
2012), aquaporin channels (Binder et al., 2012; Kovacs et al.,
2012) and Ca2+-dependent gliotransmission (Carmignoto and
Haydon, 2012). It should be taken into consideration that all
targets are chosen based on animal models, of which many are
not clinically meaningful considering the precipitating cause. In
addition, the use of human disease-affected brain tissue is of
utmost importance in the search for new drug targets, still there
are some disadvantages when human brain tissue is used for
investigation. First of all, most patients included in these stud-
ies suffered from seizures for many years and secondly, these
patients have been treated with specific AEDs. Moreover, it is
very unlikely that only one cellular or molecular pathway is
responsible for the variety of syndromes and degrees of epilepsy
(Kobow et al., 2012).
An attractive new molecular target for AEDs might be
represented by vesicular neurotransmitter transporters (VNTs)
(Figure 2). The rationale of their potential use is related on the
nature of epilepsy that is characterized by spontaneous, recur-
rent seizures, caused by abnormal synchronized, high frequency
neuronal discharges. Neuronal discharges correspond to chemi-
cal transmission, which is essential for normal communication
and functioning of the brain. This involves accumulation of neu-
rotransmitters into secretory vesicles, achieved by various types
of VNTs, followed by their exocytotic release into the extracel-
lular space (Chaudhry et al., 2008a; Omote et al., 2011). VNTs
are small proteins responsible for packing synaptic vesicles with
neurotransmitters, thereby determining the amount of neuro-
transmitter released per vesicle through fusion in both neurons
and glial cells. Based on their substrate specificity and amino
acid sequence similarity, to date, nine VNTs have been divided
into three subclasses; SLC17, SLC18 and SLC32 gene families. The
SLC17 gene family consists of the three vesicular glutamate trans-
porters (VGLUT1, VGLUT2, and VGLUT3), the vesicular excita-
tory amino acid transporter (VEAT), and the vesicular nucleotide
transporter (VNUT) (Reimer, 2013). The SLC18 gene family
comprises the vesicular monoamine transporters (VMAT1 and
VMAT2) for serotonin (5-HT), dopamine (DA), noradrenaline
FIGURE 2 | Vesicular neurotransmitter transporters depend
differentially on the two components of the electrochemical gradient
of H+ (µH+). A V-ATPase generates a μH+ across the vesicle
membranes. The vesicular transporters use this gradient to drive the
transport of transmitters into secretory vesicles by coupling the
translocation of transmitter to H+ running down μH+. The different
vesicular transporters rely to different extents on the two components
(pH and ψ) of this gradient. (A) VMATs and (B) VAChT transport their
positively charged substrates coupled to the exchange of two H+, and
hence rely primarily on pH. (C) GABA and glycine are transported as
neutral zwitterions by VGAT, which depends equally on both the chemical
and the electrical component of μH+. (D) VGLUTs transport the
negatively charged glutamate and thus rely more on ψ than pH.
[Modified from Chaudhry et al. (2008b) with permission].
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(NE) and histamine and the vesicular acetylcholine transporter
(VAChT) (Eiden et al., 2004). Finally, the SLC32 gene family
consists of the vesicular GABA transporter (VGAT) (Gasnier,
2004).
The import of neurotransmitters depends on a proton elec-
trochemical driving force (μH+) generated by the vacuolar
H+-ATPase. Despite the utmost important function of VNTs, the
main regulation of this vesicular transport remains unknown.
Two mechanisms have been suggested to modulate vesicular
transport: (1) influencing the membrane potential (ψ) by
cation and anion fluxes and (2) a direct interaction between
the heterotrimeric G-protein, Gαo2 and VNTs (Omote et al.,
2011; Blakely and Edwards, 2012; Hnasko and Edwards, 2012)
(Figure 2).
Each VNT has always been considered as a specific marker of
the respective nerve cells containing that particular neurotrans-
mitter or structurally related neurotransmitters. Recently, it has
been observed that several neuronal populations co-release clas-
sical neurotransmitters (see for a review Hnasko and Edwards,
2012). The co-transmitters might influence each other’s uptake,
by influencing the μH+, or they can be gathered in distinct
vesicles (Hnasko and Edwards, 2012). Glutamate co-release by
cholinergic neurons and monoaminergic neurons is most stud-
ied and introduced the term of “vesicular synergy,” since vesicular
co-accumulation of glutamate by vesicular glutamate transporter
3 (VGLUT3) in cholinergic and serotoninergic neurons, results in
higher vesicular import of acetylcholine (ACh) and 5-HT, respec-
tively. The anionic influx of one of the substrates of VGLUT3
(glutamate, Cl− or Pi) probably creates a lumen-positive ψ and
consequently increases the μH+ for ACh and 5-HT vesicular
accumulation (El Mestikawy et al., 2011). Due to this co-release
neurotransmission might become more complex and expose
unraveled roles for VNTs therein. Here we have reviewed the lim-
ited literature available on VNTs and epilepsy and their potential
role as treatment targets for TLE.
Yet, the only example of a vesicular protein as a target for the
treatment of epilepsy is the synaptic vesicle protein 2A (SV2A),
the binding site of levetiracetam (LEV). In vitro and ex vivo bind-
ing studies, using SV2A knock-out (−/−), heterozygous (+/−)
and wild-type (+/+) mice, identified SV2A as the binding target
for LEV. In addition, these transgenic mice were phenotyped in
kindling and distinct acute seizure models, unveiling a decreased
seizure threshold and accelerated kindling development of the
SV2A+/− mice compared to the SV2A+/+ mice. SV2A−/− mice,
on the other hand, exhibit early severe seizures and die within
2–3 weeks after birth (Kaminski et al., 2012). Other data from
these transgenic mice demonstrated the role of SV2A in modu-
lation of vesicular exocytosis (Xu and Bajjalieh, 2001; Budzinski
et al., 2009; Chang and Sudhof, 2009; Wan et al., 2010; Yao et al.,
2010; Joshi et al., 2013). Although LEV failed in classical seizure
screening tests, this drug significantly inhibited the development
of seizure kindling and displayed a potential antiepileptogenic
effect in the chronic pilocarpine post-SE rat model (Kaminski
et al., 2012). A comparative study showed a significant decrease of
SV2A protein expression in hippocampus of pharmacoresistant
human TLE patients and hippocampus of rats during the latent
and chronic phase of the pilocarpine post-SE rat model (van
Vliet et al., 2009). These data are consistent with the previously
mentioned decreased seizure threshold and accelerated epilep-
togenesis in SV2A+/− mice (Kaminski et al., 2012). Moreover,
these results might explain the loss of the initial efficacy of LEV
in refractory TLE patients (Kaminski et al., 2012; Lee et al., 2013).
At present, LEV is a worldwide commonly used second genera-
tion AED, approved as adjunctive and monotherapy treatment
of partial-onset seizures with or without secondary generaliza-
tion, and adjunctive treatment of myoclonic seizures associated
with juvenile myoclonic epilepsy and primary generalized tonic-
clonic seizures associated with idiopathic generalized epilepsy
(Lyseng-Williamson, 2011). Brivaracetam, a rationally designed
LEV derivative, which showed an increased affinity to the LEV-
binding site and more potent and complete seizure suppression
in animal models of partial and generalized seizures, is currently
tested in clinical trial studies (Kaminski et al., 2012).
These data prove that vesicular proteins are accessible and pro-
pose a promising role for proteins, involved in vesicle exocytosis,
as novel targets for the development of AEDs. Unfortunately, only
few studies have followed this concept and brivarecetam is the
only new AED in the pipeline targeting a vesicular protein. As
outlined for SV2A, results from transgenic mice, distinct acute
and chronic rodent epilepsy models and resected human epileptic
tissue are crucial to constitute a clear and complete conception of
new, potential AED targets. Consequently, in this review we will
use the same outline structure to describe the known literature
on the different VNTs in epilepsy. Unveiling and understanding
the structure of VNTs is of utmost importance to deduce their
functional domains and their physicochemical properties in order
to develop compounds that can interact with these transporters.
Therefore, we will also shortly describe and show the known VNT
structure models and the most active and used modulators of
their activity. In conclusion, we will point out the remaining chal-
lenges for research on VNTs as possible targets for future epilepsy
therapies.
SLC17 FAMILY
The SLC17 gene family consists of nine members (Reimer, 2013).
Three VGLUTs (VGLUT1, VGLUT2, and VGLUT3), the VEAT,
and the VNUT are responsible for the vesicular transport of
nucleotides and anionic neurotransmitters, glutamate and aspar-
tate. In addition, four sodium-dependent phosphate transporters
(NPT1, NPT3, NPT4, and NPT homologue) are part of this fam-
ily as well. These NPTs are not involved in neurotransmission, but
exert voltage driven organic anion elimination of toxic xenobi-
otics in the kidney and are therefore not further discussed in this
review (Omote et al., 2011).
The human SLC17 protein family is categorized as a subgroup
of anion transporters within the major facilitator superfamily
(MFS). The MFS is the largest group of secondary active trans-
porters, regulating the transport of a wide variety of substrates,
such as inorganic ions, sugars, amino acids, and xenobiotics,
across cellular and intracellular membranes (Pao et al., 1998;
Law et al., 2008). MFS proteins contain 12 transmembrane (TM)
helices, divided in two six-TM halves surrounding a central
aqueous cavity, in which the substrate-binding site is located.
Alternating opening of the binding site on one of both sides of
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the membrane is achieved by rigid body rotation of the N- and
C-terminal halves, called “rocker switch” mechanism (Abramson
et al., 2003; Law et al., 2008; Dang et al., 2010). This mechanism
enables “uphill” transport of substrate, coupled to “downhill”
transport of driving ions such as Na+ or protons (Pietrancosta
et al., 2012).
VESICULAR GLUTAMATE TRANSPORTERS
Glutamate is the most abundant and major excitatory neuro-
transmitter of the brain, mediating fast synaptic transmission
(Casillas-Espinosa et al., 2012; Mehta et al., 2013). Glutamate is
crucial for synaptic plasticity (e.g., long-term potentiation, LTP),
learning, memory and other cognitive functions. In addition, this
neurotransmitter is an important substitute source of energy for
neuronal cells in case of glucose deficiency (Mehta et al., 2013).
On the other hand, excessive glutamatergic neurotransmission
and subsequent glutamate excitotoxicity has been observed in var-
ious neurological diseases, such as epilepsy, Alzheimer’s disease,
Parkinson’s disease, multiple sclerosis and stroke. This empha-
sizes both the crucial and highly toxic role glutamate can play
in the brain and the necessity of accurate controlled extracel-
lular levels of glutamate (Casillas-Espinosa et al., 2012; Mehta
et al., 2013). VGLUTs are crucial for the storage of glutamate in
synaptic vesicles and the subsequent exocytotic release into the
synaptic cleft. Synaptic glutamate activates pre- and post-synaptic
metabotropic (mGluR) and ionotropic glutamate receptors. The
mGluRs are modulators of the synaptic glutamate signal trans-
mission. Activation of group I (mGluR 1, 5) can enhance neu-
ronal excitability, while activation of group II (mGluR 2, 3) and
III (mGluR 4, 6, 7, 8) decreases presynaptic glutamate release (see
for a review Ure et al., 2006). The ionotropic glutamate receptors
include the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA), N-methyl-D-aspartate (NMDA) and kainic acid
(KA) receptors. These glutamatergic receptors have been inten-
sively studied in both rodent epilepsymodels and human epileptic
tissue, since excessive activation of these receptors induces glu-
tamate excitotoxicity (see for a review Ghasemi and Schachter,
2011; Matute, 2011; Rogawski, 2013). KA receptors are for exam-
ple excessively stimulated by local or systemic administered KA,
a well-known proconvulsant, used in both acute and chronic
rodent epilepsy models to induce convulsions and SE (initial pre-
cipitating injury) respectively. Finally, the excitatory amino acid
reuptake transporters (EAATs) are of utmost importance for the
termination of glutamatergic neurotransmission as well as for the
prevention of neurotoxicity. In addition, system x−c has been pro-
posed as the most important source of extracellular glutamate
in mouse hippocampus and the loss of system x−c was shown
to decrease the convulsion threshold in distinct acute rodent
epilepsy models (De Bundel et al., 2011). Although the involve-
ment of glutamate transporters in epilepsy has been proven in
several animal models and human tissue, they are rarely proposed
as target for new AED development strategies (Hinoi et al., 2005;
De Bundel et al., 2011; Lewerenz et al., 2013).
VGLUTs mediate the import of glutamate into synaptic vesi-
cles. Controlling the activity of these transporters could thus
potentially modulate the efficacy of glutamatergic neurotrans-
mission (Takamori, 2006). Indeed, overexpression of VGLUT will
increase the amount of glutamate released per vesicle and as such
changes in VGLUT expression may affect quantal size and glu-
tamate release under not only physiologic, but also pathologic
conditions (Fremeau et al., 2004; Wojcik et al., 2004; Wilson et al.,
2005).
In Figures 3A,B, the 2D and 3D molecular structure of
VGLUT1 are shown, based on transmembrane segment predic-
tion and topology of bacterial MFS proteins. Filled black circles
represent residues facing the center of the pore (gray volume)
that is open to the cytoplasmic side. Three arginine residues (R80
from helix 1, R176 from helix 4, and R314 from helix 7) that are
exposed to the pore are shown in sticks. The first and last highly
variable 60 residues of the N- and C-terminal are not shown in
the 3D model (Almqvist et al., 2007).
VGLUT1 and VGLUT2 are complementarily expressed in dis-
tinct subsets of glutamatergic neurons in the central nervous
system (CNS) (Fremeau et al., 2001; Herzog et al., 2001; Varoqui
et al., 2002; Boulland et al., 2004). VGLUT1 is found in astro-
cytes of the dentate-molecular layers, the stratum radiatum of
CA1 hippocampus, the frontal cortex, and the striatum (Bezzi
et al., 2004; Zhang et al., 2004; Potokar et al., 2009; Ormel et al.,
2012a), while VGLUT2 expression is more restricted and only
observed in hippocampal astrocytes (Bezzi et al., 2004). VGLUT3
is expressed in the hippocampus, frontal cortex and in Bergmann
glia of the cerebellum. VGLUT3 is relatively more abundant and
expressed on distinct synaptic-like microvesicles (SMLVs) than
VGLUT1 (Ormel et al., 2012b). Since astrocytes express VGLUTs
on SLMVs and since only overexpression of VGLUT3 in vitro
resulted in increased Ca2+ dependent astroglial glutamate exo-
cytosis, it has been postulated that this glutamate transporter is
crucial for astroglial glutamate release (Ni and Parpura, 2009;
Ormel et al., 2012b). As already mentioned in the introduction,
VGLUT3 protein expression is observed in serotoninergic, cholin-
ergic and GABAergic neuronal populations (Fremeau et al., 2002;
Gras et al., 2002; Schafer et al., 2002; Gras et al., 2008; Seal et al.,
2008).
VGLUT1-immunoreactivity (IR) was reduced in punctate
structures of one or several layers of the peritumoral neocor-
tex of patients with epilepsy that was secondary to low-grade
tumors, a common cause of epilepsy in which the epileptogenic
region presents a loss of neurons and excitatory synapses. This
decrease was correlated with gliosis, neuronal loss, and a decrease
in the number of asymmetrical synapses (Alonso-Nanclares and
De Felipe, 2005). In TLE patients without hippocampal sclero-
sis, VGLUT1 mRNA levels were decreased, whereas VGLUT1-IR
was increased. The authors postulated that this increase could
represent a higher vesicular glutamate storage capacity, which
may increase glutamatergic transmission, and can contribute to
higher extracellular glutamate levels and excitability. In patients
with hippocampal sclerosis, on the other hand, both VGLUT1
protein and mRNA levels were decreased in subfields with severe
neuron loss, in accordance with the previous study in peritu-
moral neocortex. Furthermore, upregulated VGLUT1 reactivity
could be detected in the dentate gyrus of these patients, indicat-
ing that new glutamatergic synapses are formed in the layer with
mossy fiber sprouting (van der Hel et al., 2009). As we already
mentioned in the introduction, patients are treated with specific
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FIGURE 3 | A two and three dimensional molecular structure of the
members of the SLC17 family. (A,B) The vesicular glutamate transporter 1
(VGLUT1) (Almqvist et al., 2007), (D,E) the vesicular excitatory amino acid
transporter (VEAT) (Courville et al., 2010) and (G) the vesicular nucleotide
transporter (VNUT) (Sawada et al., 2008). (C) The different families of VGLUT
modulators (Pietrancosta et al., 2010). (F) The most bioactive analog of sialic
acid: per-O-Ac,9-iodo-Neu5Ac and the novel VEAT ligand identified by virtual
high-throughput screening: FR139317 (Pietrancosta et al., 2012). (H)
4,4′ -diisothiocyanatostilbene-2,2′ -disulfonate, the only known inhibitor of ATP
transport in vitro.
AEDs. Consequently, there is a possibility that these drugs influ-
ence VGLUT-IR. Indeed, treatment of seizure sensitive Mongolian
gerbils with high doses of valproic acid, a Na+ channel blocker,
but not vigabatrin, a GABA transaminase inhibitor, reduced the
VGLUT1/2-IR in the dentate gyrus of these animals. Moreover,
the enhanced VGLUT1/2-IR in the seizure sensitive gerbils, com-
pared with the seizure resistant animals, could be closely related
to the hyperexcitability of granule cells or the low threshold for
seizures in these gerbils (Kang et al., 2005).
Several studies investigated both VGLUT1/2 expression and/or
mRNA levels in different animal models of epilepsy. Although
models for different types of epilepsy were used, almost all stud-
ies showed increased expression of VGLUT1 or VGLUT2 in
particular brain regions. Kim et al. showed enhanced VGLUT1-
IR in both hippocampi following hypoxic ischemia, although
in this model VGLUT2 immunodensity remained unaltered
(Kim et al., 2005). On the contrary, VGLUT2 expression was
increased in regions of hippocampal heterotopia in methyla-
zoxymethanol exposed animals (Harrington et al., 2007) as
well as in the cortex of the genetic absence epilepsy rat from
Strasbourg (GAERS) (Touret et al., 2007). In the pilocarpine
model of TLE, where a striking loss of mossy cells occurs dur-
ing the latent period, VGLUT1 mRNA-containing hilar neurons
were decreased, together with an associated loss of VGLUT1-
containing terminals in the dentate gyrus inner molecular layer.
Furthermore, axonal sprouting of granule and pyramidal cells
induced aberrant VGLUT1-containing terminals at the chronic
stage. VGLUT1-IR was recovered in the inner molecular layer
and enhanced in the CA1-CA3 dendritic layers (Boulland et al.,
2007). Decreased VGLUT1 levels, detected in the human stud-
ies and in the latent period after pilocarpine-seizure induc-
tion, are possibly a reflection of the occurring neuronal loss.
The enhanced VGLUT1/2-IR in symptomatic animals displaying
chronic seizures, on the other hand, may reflect the reorganiza-
tion of the glutamatergic neurons characterized by sprouting of
glutamatergic fibers and associated neosynaptogenesis, together
with increased glutamate release in brain regions affected by
recurrent seizures (Boulland et al., 2007; Touret et al., 2007).
Therefore, in order to find out whether a severe reduction in
VGLUT2 protein can affect seizure generation and thus whether
the VGLUT2 protein is crucially involved in the origin of seizure
activity, we investigated seizure susceptibility in VGLUT2+/−
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mice. We showed that, compared to their wild-type littermates,
VGLUT2+/− mice are more susceptible to pentylenetetrazole, a
chemoconvulsant known to induce generalized seizures (Schallier
et al., 2009). These results are suggestive of an important role
for VGLUT2 in generalized seizures. However, more studies are
needed to fully understand the mechanism behind the altered
seizure susceptibility of the VGLUT2+/− mice. It would not
be surprising if compensatory up- or downregulation of pro-
teins related to glutamatergic neurotransmission occur. Indeed,
although there are no studies that investigated compensations in
the VGLUT2+/− mice, increased neuronal synthesis of glutamate,
decreased cortical and hippocampal GABA and decreased GLAST
(glutamate reuptake transporter) levels have been shown in the
VGLUT1+/− mice (Garcia-Garcia et al., 2009).
Recently, mice lacking VGLUT3 were produced to deter-
mine the physiological role of this glutamate transporter. These
VGLUT3−/− mice exhibit primary, generalized non-convulsive
epilepsy (Seal et al., 2008). Although more research should be
performed exploring the role of VGLUT3 in seizure genera-
tion and epilepsy, this observation strengthens the idea that this
transporter is possibly involved in the protection against absence
seizures.
Up to date, three types of VGLUT inhibitors (Figure 3C)
have been characterized: dyes (e.g., Rose Bengal and Trypan
Blue) (Naito and Ueda, 1985; Ozkan and Ueda, 1998; Bole
and Ueda, 2005; Almqvist et al., 2007), substituted quinolones
(e.g., quinolein dicarboxylic acid) (Bartlett et al., 1998; Carrigan
et al., 1999, 2002), and glutamate analogs [e.g., (1S,3R)-ACPD]
(Pietrancosta et al., 2010). Of these three types, dyes have the
highest affinity toward VGLUTs, especially Rose Bengal, the
only competitive inhibitor with the highest affinity of all. The
quinolones, on the other hand, display the highest selectivity,
while the glutamate analogs have only very low activity on glu-
tamate uptake, which can be explained by the low affinity of
VGLUTs toward glutamate itself (Pietrancosta et al., 2010).
VESICULAR EXCITATORY AMINO ACID TRANSPORTER
The co-localization of glutamate and aspartate was already
demonstrated in synaptic vesicles in hippocampal CA1 neu-
rons and SLMVs of pinealocytes (Fleck et al., 1993; Yatsushiro
et al., 1997; Gundersen et al., 1998). Moreover, aspartate might
be involved in both excitatory and inhibitory synapses in
the hippocampus (Gundersen et al., 1991, 1998, 2004). Only
recently, Morland and coworkers observed ATP-dependent vesic-
ular uptake of L-aspartate in the brain. Moreover, vesicular
L-aspartate uptake, relative to the L-glutamate uptake, was twice
as high in the hippocampus as in the whole brain, indicating a
crucial role of aspartate signaling in this brain region (Morland
et al., 2013). In vitro data suggest that NMDA receptor-mediated
excitotoxicity is likely caused by extrasynaptic NR1-NR2BNMDA
receptor activation by aspartate, which implicates an important
role of aspartate signaling in pathologies marked by excitotoxi-
city. However, the necessity of further studies under physiologic
conditions and the development of tools to distinguish aspartate
and glutamate postsynaptic responses was emphasized, in order
to determine the contribution of aspartate to synaptic transmis-
sion (Nadler, 2011). In addition, 30min after administration of
valproate, a broad spectrum AED, aspartate levels are significantly
decreased in both excitatory and inhibitory presynaptic nerve ter-
minals in rat hippocampus, whereas glutamate and GABA levels
remained unchanged. Consequently, the anticonvulsant effect of
valproate might be at least partly achieved by reduced extrasy-
naptic NMDA receptor-mediated excitatory signaling in the brain
(Morland et al., 2012).
Miyaji et al. unveiled the role of sialin as a vesicular aspartate
transporter in hippocampal synaptic vesicles and pineal SLMVs
(Miyaji et al., 2008). Through in vitro reconstitution of mouse
and human sialin in liposomes, it was shown that this transporter,
which is predominantly expressed in hippocampal neurons (Aula
et al., 2004; Yarovaya et al., 2005), is responsible for membrane
potential (ψ)-driven aspartate and glutamate transport into
synaptic vesicles in addition to H+/sialic acid co-transport in
lysosomes. Since aspartate and glutamate are excitatory amino
acids, the sialin transporter should be called the VEAT (Miyaji
et al., 2008, 2010, 2011).
Mutations in the SLC17A5 gene, encoding sialin, can elicit
two autosomal recessive lysosomal storage disorders: Salla disease
and infantile sialic acid storage disease (ISSD). Both disorders are
marked by accumulation of sialic acid in lysosomes (Verheijen
et al., 1999). Several studies implied a direct correlation between
the activity of sialin transport and the severity of the disease phe-
notype. Mutant forms of sialins in persons suffering from ISSD
show complete absence ofH+/sialic co-transport activity, whereas
the mutant forms of sialins found in Salla disease patients still
exhibit 20–60% of normal H+/sialic co-transport (Morin et al.,
2004; Wreden et al., 2005; Myall et al., 2007; Ruivo et al., 2008).
Salla disease and ISSD disorders predominantly affect the CNS,
eliciting varying degrees of developmental delay in motor and
cognitive skills, epilepsy, and premature death and are marked by
cytoplasmatic vacuoles and hypomyelination (Prolo et al., 2009).
Incorporation of forms of mouse and human SLC17A5 pro-
tein, associated with Salla disease, in proteoliposomes completely
abolished the aspartate and glutamate import, whereas H+/sialic
acid co-transport was significantly decreased. These results sug-
gest that loss of aspartatergic (and combined glutamatergic) neu-
rotransmission could contribute to the severe neurological defects
of Salla disease (Miyaji et al., 2008, 2010, 2011).
Figure 3D represents a 2D topology model for rat and human
sialin with manual adjustments. TM4 (shaded) traces out a large
aqueous cavity that forms a part of the substrate permeation path-
way and displays substrate-induced alterations in accessibility of
substituted cysteine residues in TM4. Mutated residues in the
lysosomal free sialic acid storage disorders are circled. The 3D
model of sialin (Figure 3E), with TM4 colored in blue and purple,
is based on the crystal structure of the glycerol 3-phosphate trans-
porter. His-183, a TM4 residue affected by a disease-associated
mutation (H183R), is depicted in red in (circle in panel D; side
chain in panel E) (Courville et al., 2010).
To further investigate potential mechanisms underlying the
pathology of the free sialic acid storage disorders, Prolo et al.
characterized sialin-deficient mice. These sialin−/− mice dis-
play poor coordination, seizures, failure to thrive, and premature
death. Histological characterization of these knock-out mice also
revealed prominent vacuolar lesions and a marked decrease in
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myelin throughout the CNS with the exception of the parasympa-
thetic nervous system. In conclusion, these mice can be used as an
appropriatemodel for free sialic acid storage disorders, since their
phenotype appears to be consistent with these disorders (Prolo
et al., 2009).
Surprisingly, Morland and coworkers could not observe a dif-
ference in ATP-dependent L-aspartate uptake in synaptic vesicles
from sialin−/− and sialin+/+ mice. Moreover, overexpression of
sialin in PC12 cells did not result in significant vesicular uptake of
L-aspartate and depolarization-induced depletion of L-aspartate
from hippocampal nerve terminals was similar in hippocampal
slices from both phenotypes. These in vitro results suggest that
either sialin is present in insufficient amounts in the vesicular
membrane, or sialin does not transport L-aspartate into synaptic
vesicles under physiological conditions, contrary to the findings
ofMiyaji et al. (2008). This discrepancy might be explained by the
fact that Miyaji and coworkers used hippocampal P2 fraction for
their studies, which is likely to contain non-vesicular membranes
and is called the crude synaptosomal fraction. Moreover, a pro-
teomic study (Takamori et al., 2006) did not detect sialin among
the other synaptic vesicle proteins, purified from rat brain. On
the other hand, no evidence was found of non-vesicular release of
L-aspartate, which confirms the exocytotic release in hippocam-
pus, though, after vesicular accumulation by another transporter
than sialin (Morland et al., 2013).
Recently, using structure-activity, homology modeling, molec-
ular docking, and mutagenesis studies, the substrate-binding site
of sialin has been successfully predicted and a 3D cytosol-open
model of sialin has been built and validated. This model pre-
dicts small molecule binding to sialin and allows screening of
new potential ligands targeting the VEAT. A first pilot virtual
high-throughput screening appointed pseudopeptide FR139317
(Figure 3F) to be a competitive inhibitor, showing >100-
fold and ∼5-fold higher affinity, than the natural substrate,
N-acetylneuraminic acid and the most bioactive analog, per-O-
Ac,9-iodo-Neu5Ac (Figure 3F) respectively. This increased activ-
ity of FR139317 may be due to novel polar interactions, in par-
ticular with TM VIII (Tyr-335) (for more details see Pietrancosta
et al., 2012).
VESICULAR NUCLEOTIDE TRANSPORTER
Burnstock was the first to indicate ATP as a neurotransmitter
and eventually its release and co-release was demonstrated in
both peripheral and CNS (Burnstock et al., 1972; Burnstock,
1976, 2007). ATP is highly concentrated (up to 100mM) in neu-
ronal, synaptic vesicles together with other nucleotides, though
at lower concentrations, and in granules in adrenal chromaf-
fin cells (Burnstock, 2007). On the other hand, Ca2+-triggered
ATP release by astrocytes has been repeatedly observed in vitro
and could be blocked by inhibition of the vacuolar H+-ATPase
(Newman, 2001; Coco et al., 2003; Pascual et al., 2005; Pangrsic
et al., 2007; Zhang et al., 2007; Pryazhnikov and Khiroug, 2008).
Vesicular astrocytic ATP is postulated to be the major, if not
the sole, determinant of astrocytic Ca2+ wave propagation in
hippocampal astrocyte cultures, mediated by G-protein coupled
P2Y1 receptors, although further studies should elucidate if astro-
cytic ATP contributes to Ca2+ waves in vivo and is involved
in neuron-glia interactions (Bowser and Khakh, 2007). In addi-
tion, the involvement of another ATP receptor, P2X7, located
on neurons and glia, has been observed in the pathophysiology
of epilepsy in distinct chronic rodent epilepsy models. However,
due to paradoxical results of P2X7 ligands in the pilocarpine
and kainate models, additional experiments in distinct rodent
epilepsy models, are needed to unveil the role of P2X7 in TLE
(Engel et al., 2012).
Astrocytic release of ATP is proposed to play a role in
hippocampal heterosynaptic depression. Extracellularly ATP is
degraded into adenosine by EctoATPases. Adenosine in turn
activates presynaptic adenosine A1 receptors and suppresses glu-
tamate release from other afferents (Pascual et al., 2005; Serrano
et al., 2006). Moreover, adenosine has been demonstrated to be
an endogenous anticonvulsant and neuroprotectant. Extracellular
adenosine levels are controlled by metabolic reuptake through
nucleoside transporters and phosphorylation by adenosine kinase
(ADK). ADK overexpression and adenosine deficiency have been
observed in different rodent models as well as in human tis-
sue resected from patients with hippocampal sclerosis and TLE
(Boison, 2012; Masino et al., 2012). Recently Masino et al. have
demonstrated that anticonvulsant effects of the ketogenic diet
are due to reduction of the expression of ADK in mice and the
enhancement of A1 receptor signaling (Masino et al., 2012).
On the other hand it has been shown that adenosine can
potentiate hippocampal neuronal activity via binding to adeno-
sine A2a receptors, without affecting presynaptic glutamate
release or postsynaptic glutamatergic conductance. Adenosine
deficiency in epilepsy can lead to decreased A2a receptor signaling
and might be an explanation for comorbidities such as disturbed
psychomotor control, sleep disorder and depression (Boison,
2012). Moreover, microdialysis experiments suggest a crucial role
of post-synaptic A2a receptors in the anticonvulsant effect of 2-
chloroadenosine and the attenuation of evoked glutamate release
by 2-chloro-N6-cyclopentyladenosine, both well-known adeno-
sine A1 receptor agonists, in the acute local pilocarpine rat model
for limbic seizures (Khan et al., 2000, 2001).
VNUT is encoded by the human and mouse SLC17A9
gene (Reimer and Edwards, 2004; Fredriksson et al., 2008;
Sreedharan et al., 2010). Proteoliposomes reconstituted with
purified, recombinant SLC17A9 transporter exhibit ψ-driven,
Cl− dependent ATP transport, similar to the ATP transporter
endogenously expressed in synaptic vesicles and chromaffin
granules. Suppression of endogenous SLC17A9 expression in
PC12 cells using small interfering RNA (siRNA) decreased KCl-
triggered release of ATP, confirming the involvement of this
transporter in vesicular storage and subsequent exocytosis of ATP
(Sawada et al., 2008).
VNUT is 430 amino acid residues long with 12 putative TM
helices with ∼23–29% identity and 41–48% similarity to that
of other SLC17 members (Figure 3G) (Sawada et al., 2008). To
the best of our knowledge we are unaware of the excistence of a
VNUT 3D model.
VNUT is predominantly expressed in the brain and adrenal
gland. Immunohistochemical studies revealed SLC17A9 protein
expression in astrocytes (Sawada et al., 2008). Whether astro-
cytic ATP is released by lysosomes (Zhang et al., 2007) or
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smaller vesicles ∼300 nm (Coco et al., 2003; Pangrsic et al., 2007;
Pryazhnikov and Khiroug, 2008) is still subject for discussion.
By contrast, ATP release from central neurons is not well-
studied. It has only recently been demonstrated that ATP
release from cultured rat hippocampal neurons is attenuated
by RNAi-mediated knockdown of VNUT. Strong VNUT-IR
is observed in the cerebellar cortex and the olfactory bulb.
In the hippocampus VNUT has been observed in both exci-
tatory and inhibitory presynaptic neurons (Larsson et al.,
2012).
Nowadays, 4,4′-diisothiocyanatostilbene-2,2′-disulfonate
(Figure 3H), also known to inhibit VGLUT, is the only inhibitor
proven to block ATP transport in vitro (Thompson et al., 2005;
Sawada et al., 2008).
SLC18 FAMILY
SLC18 transporters transport cationic neurotransmitters, such
as ACh, NE, 5-HT, DA, and histamine, into synaptic vesicles.
The SLC18 gene family consists of three members: the VMAT1,
the VMAT2, and the VAChT (Omote et al., 2011). The three
members of the SLC18 family display significant sequence homol-
ogy (Parsons, 2000; Bravo and Parsons, 2002). Similar to the
SCL17 family these transporters consists of 12 TM domains
(Wimalasena, 2010).
VESICULAR MONOAMINE TRANSPORTERS
Several studies investigated the role of monoaminergic neu-
rotransmission in the pathophysiology of epileptogenesis and
epilepsy and its co-morbidities: anxiety and depression. Direct
enhancement of hippocampal extracellular DA or 5-HT levels
has been shown to exert both anticonvulsant and antidepressant
activities (Smolders et al., 2008), although SRS in pilocarpine-
induced epileptic rats are associated with increased mesolimbic
dopaminergic activity (Cifelli and Grace, 2012). Rocha et al.
observed alterations of the dopaminergic system in the neo-
cortex of patients with TLE (Rocha et al., 2012). Moreover,
reduction of brain 5-HT levels facilitates the induction of SE by
pilocarpine administration and increases the frequency of SRS.
Activation of postsynaptic 5-HT1A receptors shows antiepilep-
tic activity in different TLE models, such as maximal dentate
activation (Orban et al., 2013). Furthermore, depletion of 5-HT
levels, after administration of 5,7-dihydroxytryptamine into the
median raphe nucleus of rats, significantly increased the inci-
dence of pilocarpine-induced SE and the frequency of seizures
during the chronic phase of this epilepsy model (Trindade-Filho
et al., 2008). NE has been proposed as a potential biomarker for
the efficacy of vagus nerve stimulation, an effective adjunctive
treatment for medically refractory epilepsy. Vagus nerve stimula-
tion enhances extracellular hippocampal NE levels, which could
be at least partly responsible for its seizure-suppressing effect
in the intrahippocampal pilocarpine rat model (Raedt et al.,
2011). Monoaminergic neurons and their projection fibers are
not only found in the cortex, striatum and thalamus, but also
in the hippocampus (Joels and Baram, 2009; Sukumar et al.,
2012). In addition, monoaminergic control of neurogenesis in
the adult midbrain (salamander) and hippocampus (rodents)
have been suggested (Park and Enikolopov, 2010; Berg et al.,
2011). In conclusion, most studies imply that upregulation of the
monoaminergic system could have anticonvulsant activity.
VMAT is responsible for the transport of monoamine neuro-
transmitters: DA, 5-HT, NE, epinephrine, and histamine, from
the cytoplasm into synaptic vesicles via a electrochemical gra-
dient generated by vacuolar type H+-ATPase (Schuldiner et al.,
1995). Two VMAT isoforms, VMAT1 and VMAT2, have been
molecularly cloned (Erickson et al., 1992; Liu et al., 1992).
Human VMAT1 is mainly expressed in peripheral endocrine cell
populations, such as the adrenal gland, whereas the expression
of human VMAT2 is largely confined to neuronal, histamin-
ergic cells. VMAT2 has a consistently higher affinity for most
monoamines, particularly histamine (Erickson et al., 1996).
Sequence analysis of human VMAT2 unveilled that most vari-
able regions are located near the N- and C-terminal and in
the large glycosylated loop between TMD I and II (Figure 4A)
(Wimalasena, 2010). Biochemical studies (Thiriot and Ruoho,
2001; Thiriot et al., 2002) demonstrated that Cys 430 in TMD XI
is essential for the recognition and binding of VMAT inhibitors.
Moreover, using a recombinant VMAT2 construct with a throm-
bin cleavage site between TMD VI and VII demonstrated that
Cys 117 in the loop between TMD I and II and Cys 324 in the
loop between TMD VII and VIII form a disulfide bond in human
VMAT2, which contributes to the structural integrity and effi-
cient monoamine transport (Wimalasena, 2010). The structure
is predicted by usingTMbase-A database of membrane span-
ning protein segments. Distinct conserved amino acids in human
VMAT1, human VMAT2, rat VMAT1, rat VMAT2, and bovine
VMAT2 are colored. The shown amino acid numbering is based
on the sequence of human VMAT2 (Wimalasena, 2010).
Three independent groups almost simultaneously published
the generation of VMAT2−/− mice. These knock-out mice show
lack of feeding behavior and die shortly after birth, which can
be partially rescued by amphetamine administration. No differ-
ences in monoaminergic cell populations and their projections
were observed in VMAT2−/− mice, however, monoamine storage
and vesicular release are severely disrupted and brainmonoamine
levels are dramatically reduced, compared to their wild-type lit-
termates (Fon et al., 1997; Takahashi et al., 1997; Wang et al.,
1997). This critical role of VMAT2 in monoamine storage in
the CNS and their subsequent exocytotic release is confirmed by
in vitro and in vivo data from VMAT2 heterozygous mice (Fon
et al., 1997) and in vitro overexpression of VMAT2 in ventral
midbrain neurons (Pothos et al., 2000).
A first minor link between epilepsy and VMAT2 was observed
in the perinatal asphyxia rat model. Perinatal asphyxia is sug-
gested to induce a variety of brain disorders, including spastic-
ity, epilepsy, mental retardation, attention deficit disorders, and
minimal brain disorder syndromes, and could be the initial trig-
ger for subsequent psychiatric and neurodegenerative diseases.
Three months after asphyxia was induced in rat pups, tyrosine
hydroxylase (TH)-IR was decreased in the striatum, hippocam-
pus, thalamus, frontal cortex, and cerebellum, while VMAT-IR
was increased in the striatum. This significant increase of VMAT2
is suggested to be a compensation for deficient dopaminer-
gic/noradrenergic innervation, as a consequence of decreased TH
(Kohlhauser et al., 1999).
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FIGURE 4 | (A) Predicted secondary structure of the human vesicular
monoamine transporter 2 (VMAT2) and (B) two classical and now commonly
used VMAT inhibitors: tetrabenazine and reserpine (Wimalasena, 2010). (C)
Three dimensional homology model of the vesicular acetylcholine transporter
(VAChT) (Khare et al., 2010) and (D) its most studied inhibitor: vesamicol
(Kozaka et al., 2012).
Following KA-induced SE both TH and norepinephrine trans-
porter (NET), but not VMAT2 mRNA levels are transiently
elevated in locus coeruleus (LC) neurons. Noradrenergic LC
efferents innervate most forebrain areas and are activated postic-
tally in epilepsy kindling models. Moreover, LC stimulation has
been demonstrated to exert seizure-suppressing effects in several
epilepsy animal models. Consequently, it is suggested that the
increase of TH and NET, responsible for synthesis and reuptake
of NE, respectively, could be an adaptive mechanism to restore
intracellular NE levels and enable LC neurons to counteract
hyperexcitability (Bengzon et al., 1999).
Only recently, it has been shown that VMAT2 protein is
mainly expressed in the cytoplasm and axons of neurons of the
hippocampus and temporal lobe cortex of rats and humans.
Moreover, the expression level of VMAT2 mRNA and protein has
been determined in resected neocortices of TLE patients (Jiang
et al., 2013) and in the hippocampus and adjacent cortices of
rats in different stages of the post-SE pilocarpine model (Jiang
et al., 2013). VMAT2 is transiently increased in the acute stage
after pilocarpine-induced epileptic seizures, but its expression is
clearly decreased after SRS in the hippocampus and temporal
lobe cortices of TLE rats. In line with this last observation, the
expression level of VMAT2 mRNA and protein in TLE patients
is significantly reduced compared to non-epileptic control sub-
jects. Taking previously mentioned studies into account, it is
suggested that the transiently increased VMAT2 might be a com-
pensatory response to enhance monoaminergic neurotransmis-
sion to counteract hyperexcitability and epileptic seizures. The
decrease in VMAT2 expression after SRS is consistent with the
known involvement of monoaminergic alterations in epileptic co-
morbidities, such as anxiety and depression, andmight contribute
to the epilepsy disease progression (Jiang et al., 2013).
The potency of two classical and now commonly used VMAT
inhibitors, tetrabenazine for VMAT2 and resperine for both iso-
forms, was confirmed on both human VMAT isoforms for almost
two decades (Erickson et al., 1996). Comparison with other
VMAT inhibitors point to the optimal positioning of the nitro-
gen and the carbonyl oxygen of tetrabenazine in the binding
site to explain the high affinity of this specific VMAT2 inhibitor.
Consequently, since resperine does not contain carbonyl oxy-
gen and nitrogens, its extended hydrophobic tail must provide
significant non-specific contribution toward its high binding
affinity. Indeed, the binding site of the transporter is known to be
particularly hydrophobic. Other inhibitors lacking these impor-
tant constituents are substantially weaker inhibitors for VMAT
in comparison with tetrabenazine and resperine (Figure 4B)
(Wimalasena, 2010).
VESICULAR ACETYLCHOLINE TRANSPORTER
ACh is secreted both centrally and peripherally, and is known
to regulate a plethora of physiological functions. Preclinical and
clinical data indicate that cholinergic activity in the entorhinal
cortex (EC), which is highly innervated by cholinergic terminals
from the basal forebrain (Lewis et al., 1967; Lysakowski et al.,
1989; Gaykema et al., 1990), may endorse and maintain epilep-
tiform discharges and kindling (Turski et al., 1989; Saucier and
Cain, 1996; Gloveli et al., 1999). The EC propagates cholinergic
activity to the stratum oriens of cornu ammonis 1 (CA1), the
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dentate hilus and many, if not all, interneurons of the hippocam-
pus. Cholinergic functions are altered in the epileptic temporal
lobe, however, the exact role and nature of these changes in
the pathogenesis of the disease are still as yet to be understood
(Friedman et al., 2007). Cholinergic dysfunction (for review see
Friedman et al., 2007) and acetylcholine-esterase (AChE) upreg-
ulation (Zimmerman et al., 2008) have been observed in the
epileptic temporal lobe, however, the exact role of these changes
in the pathogenesis of the disease are only recently demonstrated
by Gnatek et al. (2012). AChE mRNA and protein levels are fast
and strongly increased after SE in mice hippocampus (Gnatek
et al., 2012), probably as an initial attempt to maintain homeosta-
sis by reducing ACh levels and subsequently neuronal excitability
(Meshorer et al., 2005). Upregulated AChE mRNA was found
in principle and inhibitory interneurons, endothelial cells and
activated microglia (Gnatek et al., 2012). These observations
suggest a possible role in increased blood-brain barrier (BBB)
permeability (van Vliet et al., 2007; Weissberg et al., 2011) and
in microglial-mediated innate immune response (Vezzani et al.,
2011). The upregulation of AChE after SE loosens the brain’s
immune and anti-inflammatory response and facilitates epilepto-
genesis. Indeed, transgenic mice overexpressing AChE displayed
a robust increase in IL-1β mRNA levels and accelerated epilep-
togenesis compared to wild-type FVB/N mice (Gnatek et al.,
2012).
ACh acts on two different classes of receptors: muscarinic ACh
receptors (mAChRs) and nicotinergic ACh receptors (nAChRs).
Pilocarpine, a non-selective mAChR agonist, is a widely used
chemoconvulsant in both actue and chronic animal epilepsy
models (Meurs et al., 2008; Portelli et al., 2009; Bankstahl et al.,
2012; Portelli et al., 2012b). The M1mAChR is crucial for the
initiation of pilocarpine-induced seizures, and subsequent main-
tenance of these seizures necessitates NMDA receptor activation
(Maslanski et al., 1994; Smolders et al., 1997). Moreover, M1
receptor knockout mice were found to be highly resistant to
pilocarpine-induced seizures (Hamilton et al., 1997). M1 recep-
tor activation highly affects K+ conductances, such as K+ current
blockade thereby leading to a slow depolarization, blockade of the
Ca2+-dependent slow K+ current that is responsible for the after-
hyperpolarization that pursues a burst discharge, and blockade
of a transient outward K+ that regulates excitability in hip-
pocampal neurons (Millan et al., 1993; Friedman et al., 2007).
M1 receptor downregulation has been reported following seizure
induction in several models, whilst kindled animals show signifi-
cantly increased expression of both M1 and M3 receptors 28 days
following kindling (Friedman et al., 2007). The preponderance
of highly sensitive nAChRs is found presynaptically where they
stimulate neurotransmitter release, which accordingly influences
synaptic efficacy and plasticity, spike-timing-dependent plasticity,
frequency-dependent filtering as well as overall signal-to-noise
ratio in the cortex (Miwa et al., 2011). Overactivation of nAChRs
is thought to be linked to epilepsy (Picard et al., 2006; Miwa
et al., 2011). Autosomal dominant nocturnal frontal lobe epilepsy
(ADNFLE) is the first human epilepsy for which a mutation
has been described and is caused by mutations in the α4 or
β2 subunits of nAChR (Steinlein and Bertrand, 2010). ACh was
found to induce seizure-like events in both control and epileptic
hippocampal-entorhinal slices, which were completely blocked by
the non-specific muscarinic antagonist atropine, partially blocked
by the M1 receptor antagonist pirenzepine, and unaffected by the
non-specific nicotinic antagonist mecamylamine (Zimmerman
et al., 2008).
VAChT, predominantly found in synaptic vesicles, is respon-
sible for loading ACh from the cytoplasm to synaptic vesicles
(Prado et al., 2013). Like VGLUTs, VAChT appears to be a very
slow transporter and thus is prone to highly influence ACh release
(Varoqui and Erickson, 1996; Hori and Takahashi, 2012). VAChT
expression levels are known to be affected in Alzheimer’s and
Huntington’s disease (Efange et al., 1997; Smith et al., 2006;
Chen et al., 2011), however, not much is known on changes that
may occur in an epileptic brain. A 3D model of VAChT has
been designed by Schuldiner et al. based on the crystal structure
of the MFS protein glycerol-3-phosphate phosphate antiporter
(Figure 4C) (Khare et al., 2010).
Only one study is available where VAChT binding-site den-
sity was investigated in the human hippocampal formation from
epileptic patients that underwent anterior temporal lobectomy.
No reduction but rather a slight trend toward increased VAChT
binding sites was observed when compared to autopsy con-
trols, as opposed to a significant reduction in mAChRs. This
indicates the relative preservation of the cholinergic project-
ing terminals that is consistent with an axon sparing lesion
as opposed to neuronal cell loss in the process of hippocam-
pal sclerosis (Pennell et al., 1999). An explanation for the
slight increase in VAChT binding sites may be due to a rel-
ative concentration of septohippocampal presynaptic termi-
nals due to synaptic reorganization in the setting of hip-
pocampal atrophy. However, the authors do report an overall
reduction in total VAChT per hippocampal formation when
compared to autopsy controls due to significant hippocampal
atrophy.
In the preclinical setting, there is currently only one study
where the role of VAChT in epileptic mechanisms was directly
investigated using the pilocarpine animal model of epilepsy
(Guidine et al., 2008). Homozygous VAChT knock-down mice
were used, resulting in 70% less VAChT expression and a simi-
lar deficit in ACh release, since complete VAChT knock-out mice
do not survive as a result of compromised respiratory activity (De
Castro et al., 2009). These VAChT homozygous knock-downmice
were found to show hyperactivity and deficits in spatial mem-
ory acquisition as well as lack of behavioral flexibility (Martyn
et al., 2012). The authors hypothesized that innate cholinergic
hypofunction would lead to receptor upregulation, and hence an
increased susceptibility to the convulsive effects of pilocarpine.
Their hypothesis held up since the VAChT-deficient mice showed
a reduced seizure threshold following pilocarpine administra-
tion, which they propose is due to M1 receptor upregulation or
overactivation.
Finally, AChE mRNA is increased and mRNA levels of the
ACh-synthesizing enzyme choline acetyltransferase (ChAT) and
VAChT are decreased following acute stress (Kaufer et al., 1998).
Stress is still the most frequently self-reported trigger of seizures.
Moreover, enhanced severity of this stress or anxiety increases the
risk of subsequent seizures (for review see Friedman et al., 2011).
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Acute stress transiently enhances acetylcholine transmission and
neuronal excitability. Consequently, mRNA levels of the early
immediate transcription factor c-Fos, a marker of neuronal
hyperexcitation, are robustly elevated. c-Fos has binding sites
in the promotors of the previously mentioned cholinergic key
genes (AChE, ChAT and VAChT) and will consequently cause
long-lasting changes in their expression in neocortex and hip-
pocampus, resulting in a reduction in ACh levels. This delayed
secondary phase of suppressed neuronal excitability correlates
with the delayed neuropsychiatric pathologies that character-
ize post traumatic stress disorder, including depression, irri-
tability, and impaired cognitive performance (Kaufer et al.,
1998).
The location of the binding sites of Ach and vesamicol, a well-
studied inhibitor (Figure 4D), on VAChT are recently investigated
by inducing mutations, in and around W331 (Figure 4C) and
nearby the luminal end of the transporter. Hitherto, the exis-
tence of a spatial cluster of residues close to vesicular lumen,
strongly correlated with the affinitiy for ACh and vesamicol.
The cluster consists of invariant W331, highly conserved A334
and invariant F335 in TM VIII and invariant C391 in TM X
(Khare et al., 2010). However, the mechanistic model for VAChT
(Varoqui and Erickson, 1996) displaying two binding sites for
ACh, one close to cytoplasm and the other close to the vesic-
ular lumen with transfer of bound ACh between them during
transport, cannot be excluded (Khare et al., 2010). Recently, two
vesamicol analogues, o-iodo-trans-decalinvesamicol (OIDV) or
o-bromo-trans-decalinvesamicol (OBDV), were synthesized and
their affinities to VAChT were assessed by in vitro binding assays.
Both displayed greater binding affinity to VAChT than vesamicol.
Moreover, OIDV was able to penetrate the BBB and might be a
VAChT imaging probe with high affinity and selectivity (Kozaka
et al., 2012).
SLC32 FAMILY
The SLC32 gene family consists of only one member, the vesicular
GABA transporter (VGAT), responsible for the vesicular accu-
mulation of electrically neutral substrates, GABA, and glycine
(McIntire et al., 1997; Gasnier, 2004). Since GABA and glycine are
known to be inhibitory neurotransmitters, the VGAT transporter
is also called the VIAAT (Sagne et al., 1997).
Although the VNTs are divided into different families, they
were all thought to share a common overall topology with an
even number of transmembrane domains and cytosolic local-
ized N- and C-terminals. However, using epitope-specific anti-
bodies and mass spectrometry, Martens and coworkers showed
that the VGAT possesses an uneven number of transmem-
brane domains, with the N-terminus located in the cytoplasm
(Figure 5) (Martens et al., 2008).
VESICULAR GABA TRANSPORTER
As the major inhibitory neurotransmitter in the brain, GABA is
an important modulator of hyperexcitability in epilepsy patients
and experimental animalmodels. Some years agoGABA’s involve-
ment in epilepsy was suggested (Snodgrass, 1992; Roberts, 2000)
and it soon became clear that impairment of GABA functions
produced seizures, whereas enhancement resulted in an anticon-
vulsant effect (Olsen and Avoli, 1997). Accordingly, several old
(Holland et al., 1992) and more modern AEDs (Rogawski and
Loscher, 2004) act by enhancing the efficacy of GABA-mediated
mechanisms proving the GABA theory of epilepsy (Meldrum,
1989; Treiman, 2001). The exception of absence epilepsy proves
the role. Indeed, new evidence indicates that increased, rather
than decreased, GABAergic inhibition characterizes this gener-
alized form of epilepsy. In particular, enhanced tonic GABAA
inhibition, resulting from a malfunction of the astrocytic GABA
transporter GAT-1, occurs in thalamocortical neurons of all
FIGURE 5 | Refined transmembrane topology of the vesicular GABA transporter (VGAT), the only member of the SLC32 gene family (Martens et al.,
2008).
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well-established pharmacologic and genetic models of the dis-
ease (Cope et al., 2009; Di Giovanni et al., 2011). Aberrant tonic
current has also been shown to have a pathological role in TLE.
GABA receptor-mediated inhibition is reduced in the hippocampi
of animals during SE (Joshi and Kapur, 2012). SE also causes
long-term changes in plasticity of hippocampal GABA receptors
consisting of down-regulation of the subunits in the dentate gyrus
granule cells, and up-regulation in interneurons. Surprisingly,
the level of tonic inhibition in granule cells remains unchanged,
consistent with the idea that it is mediated by GABAA recep-
tors containing different subunits (Ferando and Mody, 2012).
These findings have important pharmacological implications and
extrasynaptic GABAA receptors might become an important AED
target.
Of the new AEDs recently launched, tiagabine and vigabatrin
(γ-vinyl GABA) act selectively through the GABA-ergic system.
The former inhibits neuronal and glial uptake of GABA (includ-
ing GAT-1) whilst the latter increases the synaptic concentration
of GABA by inhibition of GABA-aminotransferase. Other new
anticonvulsants are gabapentin and its structure-related prega-
balin that are GABA analogues. They easily cross the blood-brain
barrier and increase brain synaptic GABA, but their effects are
complex and have not been fully characterized (Rogawski and
Loscher, 2004; Czapinski et al., 2005). The older benzodiazepine-
like AEDs and barbiturates work with different modes of action,
through positive allosteric modulation of GABAA receptors. The
use of benzodiazepines is currently limited to acute treatment in
SE since their use in chronic therapy is characterized by negative
side effects, such as sedation, muscle relaxation, and especially
the development of tolerance and dependence (Rogawski and
Loscher, 2004).
Interestingly, VGAT activity depends equally on both pH and
ψ, differently from the other VNTs (McIntire et al., 1997). In
vitro studies have shown that VGAT in GABAergic synaptic ter-
minals acts as a co-transporter or symporter for Cl− with GABA
(Juge et al., 2009). During refilling, two Cl− ions accompany
GABA as it enters the synaptic vesicle. High rates of exchange
strongly depend on the size of the pH gradient in the vesicle
lumen vs. cytoplasm. A recent study showed that the voltage-
gated Cl− ion channel called CLC-3 co-localizes with VGAT in
perisomatic synaptic endings on CA1 pyramidal neurons and
plays a pivotal role in regulating inhibitory synaptic function by
optimizing GABA loading into presynaptic vesicles (Riazanski
et al., 2011). CLC-3 might help GABAergic interneurons to main-
tain rapid firing by ensuring optimal pH differences between
the vesicle lumen and cytoplasm, and the availability of pro-
tons for rapid GABA loading into vesicles or alternatively act as
a Cl− transporter, providing a pathway to clear the vesicle of
high Cl− concentrations (Riazanski et al., 2011). These results
are noteworthy, particularly that CLC-3−/− mice develop spon-
taneous seizures that resembled TLE with hippocampal sclerosis
and nearly complete bilateral destruction of the hippocampus
(Stobrawa et al., 2001). In CLC-3−/− mice, VGAT-dependent
GABA release is reduced and feedback inhibition is eliminated
leading to limbic seizures. With prolonged seizures, principal
neurons become excitotoxic and widespread degeneration occurs
(Naegele, 2012).
VGAT plays a fundamental role in embryonic development.
Indeed, VGAT−/− mice are not viable and die between embryonic
day (E)18.5 and birth. They exhibit a hunched posture and are
completely immobile and stiff, most likely symptoms of overexci-
tation (Wojcik et al., 2006; Saito et al., 2010). VGAT−/− foetuses
showed significant increases in both GABA and glycine contents
in the forebrain that were not derived from elevated amounts
of GABA-synthesizing enzymes. GABA and glycine accumulate
in the GABAergic and glycinergic neurons, respectively, but they
are not degraded in the glial cells of VGAT−/− mice. These
observations bear important consequences for understanding the
functional roles of VGAT from the cellular to the whole-body level
(Saito et al., 2010). It has been reported that glutamic acid decar-
boxylase (GAD)65 and not GAD67 forms a complex with heat
shock cognate 70, cysteine string protein and VGAT in the nerve
terminal. This complex appears to be the necessary machinery
required for efficient GABA synthesis and packaging into synaptic
vesicles through VGAT (Jin et al., 2003; Buddhala et al., 2009).
VGAT expression increases during development, however, in
several brain regions expression levels of VGAT are already high
at birth and in some cases they decrease in the course of brain
development (Boulland and Chaudhry, 2012). In the hippocam-
pal formation, a shift in the localization of the VGAT nerve
terminals has been observed. At early postnatal stages, they are
present in dendritic layers while later in the development they
target the perikaryon of the principal cells. This redistribution of
GABAergic nerve terminals occurs at around P7 which is also the
stage at which the postsynaptic response to GABA stimulation
switches from membrane depolarization to membrane hyper-
polarization. Thus, redistribution of GABAergic nerve terminals
together with changes in the expression of Cl− transporters is
responsible for the conversion of the GABA action from excita-
tion toward inhibition (Boulland and Chaudhry, 2012). In the
normal adult rat hippocampus, VGAT immunoreactive puncta is
strongly detected in all pyramidal cell layers of the CA1-3 regions
and the granule cell layer of the dentate gyrus (Chaudhry et al.,
1998; Kang et al., 2003; Boulland et al., 2007; Choi et al., 2010).
There is only sparse data on VGAT in human epilepsy avail-
able. In a case report of Unverricht-Lundborg disease, the most
common progressive myoclonic epilepsy, VGAT-IR was decreased
in the cortex of the examined patient (Buzzi et al., 2012). In
the resected cortex from pediatric epilepsy surgery patients with
type II cortical dysplasia GAD-labeled neurons displayed larger
somata and VGAT and GABA transporter 1 staining showed a
dense plexus surrounding cytomegalic neurons (Andre et al.,
2010). Finally, cortical tubers of tuberous sclerosis complex
patients showed decreased levels of GAD65, VGAT, GluR subunit
1 and GABAAreceptor subunits α1 and α2 (White et al., 2001).
However, until now nothing is known on VGAT in TLE patients.
As far as the experimental models of epilepsy are concerned,
the density of VGAT terminals is reduced in an animal model
of cortical dysplasia (Zhou and Roper, 2010), in pre-seizure
seizure-sensitive gerbil (Kang et al., 2003) and picrotoxin-induced
kindling rat hippocampi (Jiang et al., 2004), although VGAT-
IR is unaltered in KA-induced seizures (Sperk et al., 2003).
Contrasting evidence exists for changes in VGAT in epileptogene-
sis induced by pilocarpine. One study reported that at 1 day after
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pilocarpine-induced SE VGAT-IR is not changed (Kwak et al.,
2006), instead it is significantly reduced in the dentate gyrus at
1–2 weeks after SE and recovered to the control level at 5 weeks
after SE (Kwak et al., 2006). Conversely, other studies support an
increased rather than a decreased synthesis of VGAT that occurs
after SE and persists until the chronic stage (Boulland et al.,
2007; Choi et al., 2010). Indeed, a marked increase in VGAT-IR
in all pyramidal cell layers and the granule cell layer of den-
tate gyrus due to an up-regulation of VGAT mRNA synthesis
at 1–2 weeks reaching a maximum level of labeling at 12 weeks
after SE has been reported (Boulland et al., 2007; Choi et al.,
2010). Therefore, the increased synthesis of VGAT is likely to
lead to an increased GABA release from all remaining GABAergic
interneurons. Such increased expression of proteins is involved
in presynaptic GABAergic transmission and could be associ-
ated with increased activity of remaining interneurons (Boulland
et al., 2007). This hypothesis is supported by electrophysiologi-
cal studies showing that, in chronic pilocarpine-treated animals,
interneurons are hyperactive (Cossart et al., 2001).
A marked selective decrease in the number of VGAT mRNA-
containing neurons in the hilus of the dentate gyrus has been
observed (Boulland et al., 2007). This finding is consistent with
the cell death of GAD-containing neurons, previously demon-
strated in this model (Obenaus et al., 1993). The reduction of
VGAT-IR reported after excitotoxic insult might be also explained
by VGAT cleavage. Recently, it has been shown that VGAT is
cleaved under KA-induced conditions in vitro and in vivo giv-
ing rise to a truncated product that lacks a punctate synaptic
distribution. VGAT cleavage was mediated by calpains, and the
stability of the cleavage product suggests that the protease plays
a modulatory role rather than a destructive effect in excitotoxic
neuronal damage (Gomes et al., 2011). VGAT cleavage by calpain
leads to the formation of a new and stable truncated VGAT form
(tVGAT), which is not targeted to the synapse. This is expected
to decrease the release of GABA by exocytosis, thereby changing
the equilibrium between excitatory and inhibitory synaptic activ-
ity in the early phases after the excitotoxic insult (Gomes et al.,
2011). VGATs are not limited to hippocampal GABA interneu-
rons. Indeed, mRNA is also expressed in the dentate gyrus and
in mossy fiber synaptosomes and increase after kindling in rats
(Lamas et al., 2001). Therefore, granule cells and their mossy
fibers, besides being glutamatergic, contain the machinery for
the synthesis and vesiculation of GABA. This further supports
the notion that local synaptic molecular changes enable mossy
fibers to release GABA in response to enhanced excitability as a
protective mechanism in response to seizures (Gomez-Lira et al.,
2002).
CONCLUDING REMARKS
Epilepsy is one of the most common acquired chronic neurologic
disorders, with disastrous implications for the quality of life of
the patients. Despite the availability of a large number of AEDs,
still 30–40% of patients remain pharmacoresistant (Pitkänen
and Sutula, 2002; Baulac and Pitkanen, 2008; Pitkänen and
Lukasiuk, 2009; Abou-Khalil and Schmidt, 2012; Fridley et al.,
2012). Therefore, there is an urgent need of new non-invasive
anti-epileptogenic or disease-modifying treatments (Baulac and
Pitkanen, 2008). Several innovative targets for future AED are
currently intensively investigated. In this review we focused on the
role of VNTs in epilepsy and summarized the available evidence
in Table 1.
The future perspectives and challenges to fully elucidate the
involvement of VNTs and their subsequent possible use as targets
for the treatment of TLE are discussed below.
VGLUTs
Taken together, all the data here reviewed indicate that VGLUTs
might be involved in different types of seizures and epilepsy. As
expected VGLUTs are the most studied VNTs, although to date,
there are no data available on the expression levels of VGLUT2/3
in human epileptic tissue. Furthermore, activity studies need to be
performed. Unfortunately, although several competitive and non
competitive VGLUT inhibitors have been identified with affini-
ties into the nanomolar range (Thompson et al., 2005; Chaudhry
et al., 2008a; Pietrancosta et al., 2010), there is still a lack of spe-
cific in vivo VGLUT-inhibitors to further investigate and confirm
present consistent results.
In addition, it is worthwhile mentioning that a recent study
by Juge et al. linked fasting and excitatory neurotransmission
through Cl−-dependent regulation of VGLUT activity (Juge et al.,
2010). The ketogenic diet is often used to control epilepsy (Joshi
et al., 2013). Although fasting does not affect the activity of glu-
tamate reuptake transporters (Bough et al., 2007), the vesicular
transporters are possibly targeted by the ketone bodies, in partic-
ular acetoacetate and β-hydroxybutyrate, produced by this diet.
These metabolites can enter the brain, serving as substrates for
energy production in neurons. Ketone bodies can compete with
Cl−, an anion which is absolutely necessary for optimal VGLUT
functioning, by shifting the Cl− dependence to a higher concen-
tration. Furthermore, Juge et al. showed that acetoacetate can
reversibly suppress glutamate release and seizures evoked by 4-
aminopyridine in the brain. Thus, the competitive interaction
between Cl− and ketone bodies can turn VGLUT activity off
upon binding of the latter, causing a reduction in glutamatergic
neurotransmission in vivo. The identification of ketone bodies as
physiological modulators of VGLUTs advances the search for new
approaches in the development of drugs to treat neurological dis-
orders caused by excessive glutamatergic neurotransmission, such
as epilepsy (Juge et al., 2010).
VEAT
The role of sialin in epilepsy and epileptogenesis is far from
known. Moreover, the involvement of sialin in the vesicular load-
ing of aspartate has recently been questioned, based on in vitro
data from sialin(−/−) mice (Morland et al., 2013). Of course, it
cannot be excluded that these transgenic mice develop compen-
satory mechanisms to counteract the loss of sialin. Consequently,
there is a need for the development of specific inhibitors of sialin
to confirm the role of sialin as VEAT in vivo.
Currently commercial antibodies cannot be used for
immunolocalization of sialin and from previous immunohisto-
chemical studies (Aula et al., 2004; Yarovaya et al., 2005), using
“home-made” anti-sialin antibodies, presence in synaptic vesicles
could not be confirmed. Therefore, production of new distinct
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Table 1 | Summary of literature regarding transgenic mice with disruptions in vesicular nucleotide transporters (VNTs) in different models of
seizures and epilepsy, as well as the known alterations and reorganizations in the expression levels of these VNTs in rodent models for
temporal lobe epilepsy (TLE) and in human tissue resected for epilepsy surgery.
Human epileptic
tissue
mRNA/protein
alterations
References Animal epilepsy
models/transgenic
animals
Alterations
mRNA/protein/seizure
threshold
References
VGLUT1 Punctate structures
of the peritumoral
neocortex
Protein level ↓ Alonso-Nanclares
and De Felipe, 2005
Seizure sensitive gerbils
(Snodgrass)
Protein level ↑ Kang et al., 2005
TLE without
hippocampal
sclerosis
mRNA level ↓ van der Hel et al.,
2009
Hypoxic ischemia (both
hippocampi)
Protein level ↑ Kim et al., 2005
Protein level ↑ van der Hel et al.,
2009
Post-SE pilocarpine
model [latent period, hilar
neurons, dentate gyrus
(DG)]
mRNA level ↓ Boulland et al.,
2007
TLE with
hippocampal
sclerosis (subfields
with neuronal loss)
mRNA level ↓ van der Hel et al.,
2009
Post-SE pilocarpine
model (chronic period,
CA1-CA3)
Protein level ↑ Boulland et al.,
2007
Protein level ↓ van der Hel et al.,
2009
TLE with
hippocampal
sclerosis
(DG)
Protein level ↑ van der Hel et al.,
2009
VGLUT2 No studies Seizure sensitive gerbils
(DG)
Protein level ↑ Kang et al., 2005
Hypoxic ischemia (both
hippocampi)
Protein level unaltered Kim et al., 2005
Methylazoxymethanol
explosion (hippocampus)
Protein level ↑ Harrington et al.,
2007
Symptomatic GAERS
(cortex)
Protein level ↑ Touret et al.,
2007
VGLUT2(+/−) Seizure threshold ↓
(pentylenetetrazole)
Schallier et al.,
2009
VGLUT3 No studies VGLUT3(−/−) Spontaneous absence
seizures
Seal et al., 2008
VEAT No studies Sialin(−/−) Spontaneous seizures Prolo et al., 2009
VNUT No studies No studies
VMAT2 Medically
intractable TLE
(neocortices)
mRNA level ↓ Jiang et al., 2013 Perinatal asphyxia rat
model (striatum)
Protein level ↑ Kohlhauser
et al., 1999
Protein level ↓ Jiang et al., 2013 Following KA-induced
status epilepticus (locus
coeruleus)
mRNA level unaltered Bengzon et al.,
1999
Acute stage post-SE
pilocarpine model
(hippocampus and
cortex)
Protein level ↑ Jiang et al., 2013
After SRS post-SE
pilocarpine model
(hippocampus and
cortex)
Protein level ↓ Jiang et al., 2013
(Continued)
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Table 1 | Continued
Human epileptic
tissue
mRNA/protein
alterations
References Animal epilepsy
models/transgenic
animals
Alterations
mRNA/protein/seizure
threshold
References
VAChT TLE with
hippocampal
sclerosis
Protein level ↑
trend
Pennell et al., 1999 homozygous VAChT
knock-down mice
Seizure threshold ↓
(pilocarpine)
De Castro et al.,
2009
VGAT Unverricht-
Lundborg disease
(cortex)
Protein level ↓ Buzzi et al., 2012 Cortical dysplasia (CD) Protein level ↓ Zhou and Roper,
2010
Pediatric epilepsy
type II (CD) (cortex)
Dense plexus
surrounding
cytomegalic
neurons
Andre et al., 2010 Seizure sensitive gerbils Protein level ↓ Kang et al., 2003
Tuberous sclerosis
complex (cortical
tubers)
mRNA level ↑ White et al., 2001 Picrotoxin-induced
kindling
Protein level ↓ Jiang et al., 2004
KA-induced seizures Protein level unaltered Sperk et al.,
2003
Post-SE pilocarpine
model (hippocampus, 1
day)
Protein level unaltered Kwak et al., 2006
Post-SE pilocarpine
model (1–2 weeks only
DG)
Protein level ↓ Kwak et al., 2006
Post-SE pilocarpine
model (5 weeks only DG)
Protein level unaltered Kwak et al., 2006
Post-SE pilocarpine
model (hilus of the DG
1–12 weeks)
Number of VGAT
mRNA-containing
neurons ↓
Boulland et al.,
2007
Post-SE pilocarpine
model (hippocampus
1–12 weeks)
mRNA level ↑ (time
dependent)
Boulland et al.,
2007
Post-SE pilocarpine
model (hippocampus
1–12 weeks)
Protein level ↑ (time
dependent)
Boulland et al.,
2007
anti-sialin antibodies, which can be tested for specificity in both
Western Blotting and immunohistochemistry in sialin(−/−) vs.
wiltype brain tissue, is necessary.
However, since sialin(−/−) mice clearly exhibit seizures, this
transporter, whether or not crucial for vesicular import of aspar-
tate, still might be a novel AED target. Subsequently, the currently
available tools should be used to further investigate this role. The
seizure threshold of sialin(+/−) can be compared to their wildtype
littermates in different animal models for epilepsy and moreover,
the expression levels of VEAT in human epileptic tissue should be
determined.
VNUT
The lack of tools is a major issue in order to unravel the possible
involvement of VNUT in epilepsy and epileptogenesis. Although
ADK overexpression and adenosine deficiency are considered
to be pathological hallmarks in distinct rodent models and in
human tissue resected from TLE patients (Boison et al., 2012),
still nothing is known aboutmRNAor protein expression levels of
VNUT in those tissues. Surprisingly, only one home-made anti-
body against VNUT has been described until now (Larsson et al.,
2012). Moreover, the development of specific inhibitors might
provide more insights in the role of VNUT in epilepsy as well.
VMAT
A few studies, including both animal models for epilepsy and
human epileptic tissue, indicate the possible involvement of
VMAT in acute seizure generation and epileptogenesis.
Recently, Narboux-Neme et al. generated a conditional dele-
tion of VMAT2 in raphe 5-HT neurons by Cre-recombinase
expressed under the control of the 5-HT transporter gene
(SERT, slc6a4) promoter. These VMAT2sert−cre mice show an
almost complete depletion of 5-HT in the brain. Nonetheless,
raphe neurons are normally developed and exert normal inner-
vations of target regions. The conditional VMAT2−/− results
in a depressive-like phenotype and an anxiety-like response
(Narboux-Neme et al., 2011). To further investigate whether
VMAT inhibition would indeed negatively affect the course of
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disease progression in epilepsy, these inhibitors could be adminis-
trated at different stages of the chronic post-SE pilocarpinemodel
(Jiang et al., 2013). Similarly, it would be most interesting to
subject the conditional VMAT2−/− mice to chronic models of
epilepsy.
VAChT
The precise role VAChT plays in epilepsy still needs to be unrav-
eled. The sparse data from human epileptic tissue and homozy-
gous VAChT knock-down mice, suggest that inhibition of this
VNT might lead to protection against seizures. However, cholin-
ergic neurotransmission in the hippocampus is linked to cogni-
tive functions, such as learning and memory. Hippocampal LTP
is negatively affected in homozygous VAChT knock-down mice,
which is of great importance in learning and memory processes
(Martyn et al., 2012; Bliss and Collingridge, 2013). This indicates
that a substantial attenuation of VAChT, consequently leading
to hippocampal cholinergic deficits, may not be ideal in the
clinical situation. Incidentally, cognitive and behavioral impair-
ments are co-morbidities associated with epilepsy (Berg, 2011).
Neuropharmacologists aim to find AED treatments that not only
suppress seizures and hinder the epileptogenic process, but also
prohibit any cognitive dysfunctions in patients with TLE. In an
attempt to prevent or reduce worsening of epilepsy-related co-
morbidities together with attenuating epileptic seizures, it would
be of interest to investigate the actions of VAChT blockers, in
animal models of epilepsy to confirm whether similar effects on
seizures, epilepsy progression and cognitive functioning will be
obtained as in the VAChT knock-down mouse model.
VGAT
Despite the fact that no drugs acting specifically on VGAT have
been identified to date, it has been shown that vigabatrin inhibits
VGAT with an affinity similar to GABA (McIntire et al., 1997), an
effect that is present only acutely and is lost after chronic treat-
ment with vigabatrin (Engel et al., 2001). This could explain the
proconvulsant effect of vigabatrin during the first hours following
its administration (Löscher et al., 1989). Selective high-affinity
VGAT inhibitors should broadly impair inhibition and would
thus be of limited therapeutic interest. Still, they could have pro-
vided probes for in vivo imaging of inhibitory nerve terminals
in the human brain, with potential applications for monitor-
ing the progression or treatment of neurodegenerative diseases
characterized by a loss of GABAergic neurons such as epilepsy,
Huntington’s disease, and brain ischemia. These transporters are
particularly interesting as specific markers for GABAergic neu-
rons whose expression levels could reflect the demand for synaptic
transmission and their average activity. This could be used in
addition to the earlier described intrahippocampal injection of
fluorochromated anti-VGAT-C in mice for specific GABAergic
synapses labeling in vivo (Martens et al., 2008).
Moreover, an interesting strategy for new AEDs targeting
VGAT might be related to its expression. For instance, vigaba-
trin has been shown to be capable of increasing VGAT-IR in
the gerbil hippocampus following spontaneous seizures (Kang
et al., 2003). Similarly, the opening of ATP-sensitive potassium
(KATP) channels by diazoxide prevented seizures and resulted in
an up-regulation of VGATmRNAs and VGAT protein production
in hippocampus, and a down-regulation of GAT-1 and GAT-3
gene and protein expressions in picrotoxin-induced kindling in
rats (Jiang et al., 2004).
Consequently, epigenetics and microRNA (miRNA) con-
trollers should be considered as hot topic therapeutic interven-
tions to regulate VNTs expression levels.
Epigenetics is defined as information that is heritable during
cell division other than the DNA sequence itself, including DNA
methylation or histone tail modifications, which can produce
lasting alterations in chromatin structure and gene expression
(Kobow and Blumcke, 2011). The methylation hypothesis of
Kobow and Blümcke postulates that seizures are able to induce
epigenetic chromatin modifications and consequently deteriorate
epileptogenesis and contribute to structural brain lesions and
cognitive dysfunction (Kobow and Blumcke, 2011). Moreover,
parallel as in cancer, epigenetic modifications can affect mul-
tidrug transporters and induce pharmacoresistance in epilepsy
(Kobow et al., 2013). Distinct histone deacetylase and DNA
methyltransferase inhibitors are currently under clinical investi-
gation as possible novel epigenetic treatment strategies (Kobow
and Blumcke, 2011). More research on epigenetic chromatin
modifications will certainly lead to a better understanding of the
pathomechanisms involved in epileptogenesis and to novel pos-
sible antiepileptogenic compounds or biomarkers (for review see
Lubin, 2012; Roopra et al., 2012). For example in prostate cancer,
SCL18A2 hypermethylation was observed in ∼90% of all cases,
subsequently epigenetic silencing of VMAT2 was defined as a
novel adverse predictor of biochemical recurrence after radical
prostatectomy (Sorensen et al., 2009).
miRNA on the other hand is a group of small non-coding
RNA able to control post-transcriptional gene expression by fine-
tuning protein production, through sequence-specific binding
within the 3′ untranslated region of mRNA transcripts (Jimenez-
Mateos and Henshall, 2013). This translational control of miRNA
is observed in neurons (Kosik, 2006), astroytes (Tao et al., 2011)
and microglia (Ponomarev et al., 2011) and seems to be involved
in the process of epileptogenesis as well as the maintenance and
progression of the epileptic state (for review see Jimenez-Mateos
and Henshall, 2013). By use of genome-wide miRNA profil-
ing in human hippocampus of autopsy control and mesial TLE
patients with and without hippocampal sclerosis, three distinct
miRNA signatures were observed. Moreover, deregulated miRNA
targets components of key pathways in TLE, including VGLUT1
(Kan et al., 2012). Although several approaches have been exam-
ined to modulate individual miRNA expression, such as viral
vectors, miRNA decoys and miRNA “sponges,” a better under-
standing of miRNA biology and function is necessary before an
eventually clinical translation of these possible new therapeutic
interventions (for review see Brown and Naldini, 2009).
CONCLUSION
Epilepsy remains a hard-to-treat disorder for millions of patients.
There is an urgent need of non-invasive antiepileptogenic or
disease-modifying treatments. VNTs are appealing new intracel-
lular targets for future AEDs. Nevertheless, LEV and brivarac-
etam are, respectively, hitherto the only approved AED and the
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only AED currently in the pipeline targeting a vesicular protein
(Kaminski et al., 2012). Muchmore research is needed to improve
our understanding of the role of VNTs in normal and pathological
conditions, as this will certainly lead to new therapeutic strategies
for TLE and other CNS disorders.
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